Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21999580 | 0.90 | ACLY (1.00) | ACLY | |
| SCHEMBL21999891 | 0.89 | ACLY (1.00) | ACLYMCL1 | |
| SCHEMBL21999582 | 0.88 | ACLY (1.00) | ACLY | |
| SCHEMBL21999730 | 0.86 | ACLY (1.00) | ACLYMCL1 | |
| SCHEMBL7686172 | 0.83 | ACLY (0.71) | ACLYMCL1 | |
| SCHEMBL2276451 | 0.83 | ACLY (0.71) | ACLYMCL1 | |
| SCHEMBL6137932 | 0.82 | ACLY (0.69) | ACLY | |
| SCHEMBL2273163 | 0.80 | ACLY (0.67) | ACLYMCL1 | |
| SCHEMBL27716715 | 0.80 | ACLY (0.67) | ACLYMCL1 | |
| SCHEMBL21931063 | 0.78 | ACLY (1.00) | ACLYMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885MCL1 2618/4885 |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885MCL1 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.